European cancer mortality predictions for the year 2025 with focus on breast cancer

Background: We predicted the number of cancer deaths and rates for 2025 in the European Union (EU), its five most populous countries, and the UK, focusing on breast cancer. Materials and methods: We derived population data and death certificates for all cancers and major sites for the EU, databases. Estimates for 2025 were computed by linear regression on recent trends identified through Poisson joinpoint regression, considering the slope of the most recent trend segment. Deaths averted from 1989 to 2025 were calculated by applying the 1988 peak rate to subsequent population data. Results: We estimated 1280000 cancer deaths in the EU in 2025, corresponding to age-standardised rates (ASRs) of 120.9/100000 males (-3.5% versus 2020) and 79.1/100000 females (-1.2%). In the UK, we predicted 173000 cancer deaths and ASRs of 101.2/100000 males (-10.1%) and 82.1/100000 females (-6.3%). In the EU, favourable trends are predicted for major neoplasms, except pancreatic cancer, in males (+2.0%) and females (+3.0%), and lung (+3.8%) and bladder (+1.9%) cancers among females. Breast cancer mortality showed favourable trends in all countries. Substantial decreases were predicted for EU females aged 50-69 years (-9.8%) and 70-79 years (-12.4%). Between 1989 and 2025, we estimated about 6.8 million averted cancer deaths in the EU, including over 373000 breast cancer deaths. Corresponding numbers for the UK were 1500000 and 197000. Conclusion: EU breast cancer rates have fallen by 30% since 1990, due to advances in prevention, treatment, and early detection. Contrasting trends in lung cancer among males and females reflect differing tobacco smoking patterns. Female lung cancer mortality is still increasing in the EU, though less than in the previous decade. Persistent unfavourable pancreatic cancer trends can be related to the increasing prevalence of obesity and limited therapeutic advances, requiring continued attention.